Advertisement

Digestive Diseases and Sciences

, Volume 52, Issue 9, pp 2095–2103 | Cite as

Aggravation by Selective COX-1 and COX-2 Inhibitors of Dextran Sulfate Sodium (DSS)-Induced Colon Lesions in Rats

  • Mitsuaki Okayama
  • Shusaku Hayashi
  • Yoko Aoi
  • Hikaru Nishio
  • Shinichi Kato
  • Koji TakeuchiEmail author
Original Article

Abstract

We examined the effect of cyclooxygenase (COX) inhibitors on dextran sulfate sodium (DSS)-induced ulcerative colitis in rats and investigated the role of COX isozymes in the pathogenesis of this model. Experimental colitis was induced by treatment with 2.5% DSS in drinking water for 6 days. Indomethacin (a nonselective COX inhibitor), SC-560 (a selective COX-1 inhibitor), or celecoxib (a selective COX-2 inhibitor) was given PO twice daily for 6 days, during the first 3 or last 3 days of the experimental period. Daily treatment with 2.5% DSS for 6 days caused damage to the colon, with a decrease in body weight gain and colon length as well as an increase of myeloperoxidase (MPO) activity. All COX inhibitors given for 6 days significantly worsened the severity of DSS-induced colonic damage with increased MPO activity. The aggravation was also observed by SC-560 given for the first 3 days or by celecoxib given for the last 3 days. The expression of COX-2 mRNA in the colon was upregulated on day 3 during DSS treatment, with significant increase of prostaglandin E2 PGE2 production. The PGE2 content on day 3 during DSS treatment was inhibited by both indomethacin and SC-560, but not by celecoxib; on day 6 it was suppressed by both indomethacin and celecoxib, but not SC-560. These results suggest that endogenous prostaglandins (PGs) afford protection against colonic ulceration, yet the COX isozyme responsible for the production of PGs differs depending on the stage of ulceration; COX-1 in the early stage and COX-2 in the late stage.

Keywords

Dextran sulfate sodium-induced colon lesion Nonsteroidal anti-inflammatory drug Prostaglandin Cyclooxygenase (COX) Selective COX-1 and COX-2 inhibitors 

Notes

Acknowledgments

This research was supported in part by the Open Research Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

  1. 1.
    Simmonds NJ, Rampton DS (1993) Inflammatory bowel disease—a radical view. Gut 34:865–868PubMedGoogle Scholar
  2. 2.
    Suematsu M, Suzuki M, Kitahora T, Miura S, Suzuki K, Hibi T, Watanabe M, Nagata H, Asakura H, Tsuchiya M (1987) Increased respiratory burst of leukocytes in inflammatory bowel: the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol 24:125–128PubMedGoogle Scholar
  3. 3.
    Shiratora Y, Aoki S, Takada H, Kiriyama H, Ohto K, Hai K, Teraoka H, Matano S, Matsumoto K, Kamii K (1989) Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 44:163–171PubMedCrossRefGoogle Scholar
  4. 4.
    Hirata I, Murano M, Nitta M, Sasaki S, Toshina K, Maemura K, Katsu K (2001) Estimation of mucosal inflammatory mediators in rat DSS-induced colitis. Digestion 63:73–80PubMedCrossRefGoogle Scholar
  5. 5.
    Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344–1350PubMedGoogle Scholar
  6. 6.
    Mizuno H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387–397PubMedCrossRefGoogle Scholar
  7. 7.
    Ukawa H, Yamakuni H, Kato S, Takeuchi K (1998) Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on gastric ulcerogenic and healing responses in experimental animals. Dig Dis Sci 43:2003–2011PubMedCrossRefGoogle Scholar
  8. 8.
    Shigeta J, Takahashi S, Okabe S (1998) Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 286:1383–1390PubMedGoogle Scholar
  9. 9.
    Halter F, Tarnawski AS, Schmassmann A, Peskar BM (2001) Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49:443–453PubMedCrossRefGoogle Scholar
  10. 10.
    Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D (1993) Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361–368PubMedCrossRefGoogle Scholar
  11. 11.
    Kargman S, Charlesion S, Cartwright M, Frank J, Riendeaw D, Mancini J, Evans JG (1993) Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111:445–454CrossRefGoogle Scholar
  12. 12.
    O’Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330:156–160PubMedCrossRefGoogle Scholar
  13. 13.
    Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297–306PubMedCrossRefGoogle Scholar
  14. 14.
    Wallace JL, McKnight W, Reuter BK, Vergnolle N (2000) NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:706–714PubMedCrossRefGoogle Scholar
  15. 15.
    Tanaka A, Araki H, Komoike Y, Takeuchi K (2001) Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol (Paris) 95:21–27CrossRefGoogle Scholar
  16. 16.
    Tanaka A, Hase S, Miyazawa T, Takeuchi K (2002) Up-regulation of COX-2 by inhibition of COX-1: A key to NSAID-Induced intestinal damage. J Pharmacol Exp Ther 300:754–761PubMedCrossRefGoogle Scholar
  17. 17.
    Araki H, Komoike Y, Matsumoto M, Tanaka A, Takeuchi K (2002) Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats. Digestion 66:145–153PubMedCrossRefGoogle Scholar
  18. 18.
    Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y (2000) Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608–1616PubMedCrossRefGoogle Scholar
  19. 19.
    Ogawa Y, Kanatsu K, Iino T, Kato S, Jeong YI, Shibata N, Takata K, Takeuchi K (2002) Protection against dextran sulfate sodium-induced colitis by microspheres of ellagic acid in rats. Life Sci 71:827–839PubMedCrossRefGoogle Scholar
  20. 20.
    Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S (1994) NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclo-oxygenase (COX-2) activity in vitro. Prostaglandins 47:55–59PubMedCrossRefGoogle Scholar
  21. 21.
    Tso JY, Sun X-H, Kao T-H, Reece KS, Wu R (1995) Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucleic Acids Res 13:2485–2502CrossRefGoogle Scholar
  22. 22.
    Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D (1993) Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361–368PubMedCrossRefGoogle Scholar
  23. 23.
    Sasaki S, Hirata I, Maemura K, Hamamoto N, Murano M, Toshina K, Katsu K (2000) Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol 51:23–28PubMedCrossRefGoogle Scholar
  24. 24.
    Nitta M, Hirata I, Toshina K, Murano M, Maemura K, Hamamoto N, Sasaki S, Yamauchi H, Katsu K (2002) Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329. Scand J Immunol 56:66–75PubMedCrossRefGoogle Scholar
  25. 25.
    Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, Ichikawa A, Narumiya S (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109:883–893PubMedCrossRefGoogle Scholar
  26. 26.
    Cooper, HS, Murthy SNS, Shah RS, Sedergran DJ (1993) Clinicopathological study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238–249PubMedGoogle Scholar
  27. 27.
    Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB (1999) Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 116:310–319PubMedCrossRefGoogle Scholar
  28. 28.
    Okayama M, Tsubouchi R, Kato S, Takeuchi K (2004) Protective effect of lafutidine, a novel histamine H2-receptor antagonist, on dextran sulfate sodium-induced colonic inflammation through capsaicin-sensitive afferent neurons in rats. Dig Dis Sci 49:1695–1702CrossRefGoogle Scholar
  29. 29.
    Kunikata T, Umeda M, Tanaka A, Kato S, Takeuchi K (2002) 16,16-dimetyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 47:894–904PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka A, Mizoguchi H, Kunikata T, Miyazawa T, Takeuchi K (2001) Protection by constitutively formed nitric oxide of intestinal damage induced by indomethacin in rats. J Physiol Paris 95:35–41PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Mitsuaki Okayama
    • 1
  • Shusaku Hayashi
    • 1
  • Yoko Aoi
    • 1
  • Hikaru Nishio
    • 1
  • Shinichi Kato
    • 1
  • Koji Takeuchi
    • 1
    Email author
  1. 1.Department of Pharmacology and Experimental Therapeutics Kyoto Pharmaceutical UniversityMisasagiYamashinaJapan

Personalised recommendations